C12Y 304/21112
Site-1 protease , i.e. subtilisin kexin isozyme-1
Official title: Site-1 protease (3.4.21.112), i.e. subtilisin kexin isozyme-1
C12Y304/21112 (Site-1 protease , i.e. subtilisin kexin isozyme-1) appears on 10 US grants and 18 published applications in this corpus.
Search patents in C12Y- Granted patents
- 10
- Published applications
- 18
- Assignees
- 10
- Inventors
- 35
- Latest grant
- 10 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 1 | 2 |
| 2017 | 0 | 2 |
| 2018 | 1 | 1 |
| 2019 | 1 | 2 |
| 2020 | 0 | 1 |
| 2021 | 1 | 2 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
| 2024 | 2 | 2 |
| 2025 | 0 | 0 |
| 2026 | 2 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Antisense nucleic acid targeting PCSK910 Feb 2026US 12,544,449 B2National Cerebral and Cardiovascular Center
- Subtilase variants20 Jan 2026US 12,529,016 B2Novozymes A/S
- Treatment for skeletal diseases caused by intracellular protein trafficking defects9 Jul 2024US 12,031,136 B2Oklahoma Medical Research Foundation
- Subtilase variants9 Apr 2024US 11,952,558 B2Novozymes A/S
- Antisense nucleic acid targeting PCSK915 Mar 2022US 11,273,222 B2National Cerebral and Cardiovascular Center
- Treatment for Skeletal Diseases Caused by Intracellular Protein Trafficking Defects12 Sep 2024US 2024/0301427 A1
- Subtilase variants25 Apr 2024US 2024/0132807 A1Novozymes A/S
- Antagonist of pcsk915 Jun 2023US 2023/0183694 A1Argonaute Rna Limited
- Antisense nucleic acid targeting pcsk926 May 2022US 2022/0160880 A1National Cerebral and Cardiovascular Center
- Subtilase variants29 Jul 2021US 2021/0230516 A1Novozymes A/S
Most cited
By later US patents
- Inhibition of PCSK9 through RNAi48US 9,493,774 B2RXi Pharmaceuticals Corporation · 2016
- Inhibition of PCSK9 through RNAI21US 10,167,471 B2RXi Pharmaceuticals Corporation · 2019
- Subtilase variants3US 10,995,304 B2Novozymes A/S · 2021
- Antisense nucleic acid targeting PCSK91US 11,273,222 B2National Cerebral and Cardiovascular Center · 2022
- Subtilase variants1US 11,952,558 B2Novozymes A/S · 2024